BRD2 (Bromodomain-containing protein 2) variants and mutations
BRD2 (also known as Bromodomain-containing protein 2) is a human protein-coding gene encoding a bromodomain-containing protein 2 protein. It recognizes acetylated chromatin and recruits transcriptional machinery that helps regulate cell-cycle and lineage-specific gene expression. Altered BRD2 dosage or activity has been implicated in cancer, inflammation, and neurological disease, and it is inhibited by BET-family bromodomain drugs. This analysis covers 1,692 BRD2 variants and mutations. Of these, 63% have computational variant effect predictions. Disease context includes neurodegenerative disease, neoplasm, and Alzheimer disease. Example BRD2 variants include M1V, p.Met5 Pro6delinsThr, and M1L.
Variant analysis overview
- Gene: BRD2
- Protein: Bromodomain-containing protein 2
- UniProt accession: P25440
- Organism: Homo sapiens
- Variants analyzed: 1692
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 1,372 unspecified-consequence records; 210 missense variants; 26 frameshift variants; 62 synonymous variants; 4 in-frame deletions; 13 stop-gained variants; 2 in-frame insertions; 2 stop lost; 1 stop retained variant
- Prediction scores: 1,067 variants have prediction scores (63% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodegenerative disease, neoplasm, Alzheimer disease, Parkinson disease, multiple sclerosis, myelofibrosis, lysosomal storage disease, autoimmune disorder of central nervous system, cardiovascular disorder, hematopoietic and lymphoid cell neoplasm, type 2 diabetes mellitus, COVID-19.
Protein structure and variant hotspots
- Protein features: 3 domains; 7 binding sites; 7 post-translational modification sites.
- Structural context: 591 variants have structural context.
- PTM context: 19 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable BRD2 variants
Examples include M1V, p.Met5 Pro6delinsThr, M1L, M1T, M1I, L2R, L2I, L2F. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), gnomAD 6-32969258-A-G, CADD 1.97
- p.Met5 Pro6delinsThr, rs1442669762, gnomAD 6-32969258-ATGC-A, CADD 9.60
- M1L (p.Met1Leu), gnomAD 6-32969258-A-C, CADD 1.73
- M1T (p.Met1Thr), gnomAD 6-32969259-T-C, CADD 8.82
- M1I (p.Met1Ile), gnomAD 6-32969260-G-T, CADD 9.50
- L2R (p.Leu2Arg), TOPMed rs1345703139, gnomAD rs1345703139, REVEL 0.17, CADD 27.50
- L2I (p.Leu2Ile), gnomAD 6-32969255-C-A, CADD 10.80
- L2F (p.Leu2Phe), rs1353504538, gnomAD 6-32969255-C-T, CADD 11.60
- L2P (p.Leu2Pro), gnomAD 6-32969256-T-C, CADD 12.90
- L2H (p.Leu2His), gnomAD 6-32969256-T-A, CADD 12.40
- L2L (p.Leu2Leu), gnomAD 6-32969257-C-A, CADD 13.20
- Q3* (p.Gln3Ter), TOPMed rs1778214145, gnomAD rs1778214145, CADD 39.00
- Q3L (p.Gln3Leu), TOPMed rs1778214395, gnomAD rs1778214395, REVEL 0.14, CADD 26.10
- Q3K (p.Gln3Lys), gnomAD 6-32969336-C-A, CADD 16.90
- Q3H (p.Gln3His), gnomAD 6-32969338-G-T, CADD 17.20
- Q3S (p.Gln3Ser), gnomAD 6-32969338-GC-G, CADD 15.80
- Q3Q (p.Gln3Gln), gnomAD 6-32969338-G-A, CADD 17.60
- N4K (p.Asn4Lys), cosmic curated COSV66373
- V5A (p.Val5Ala), ExAC rs765229853, TOPMed rs765229853, gnomAD rs765229853, REVEL 0.12, CADD 25.70
- V5E (p.Val5Glu), cosmic curated COSV66372
- V5M (p.Val5Met), gnomAD rs1396038421, REVEL 0.10, CADD 26.00
- V5I (p.Val5Ile), rs1189311115, gnomAD 6-32969288-G-A, CADD 16.80
- V5L (p.Val5Leu), gnomAD 6-32969288-G-C, CADD 16.50
- V5F (p.Val5Phe), gnomAD 6-32969288-G-T, CADD 16.40
- V5D (p.Val5Asp), gnomAD 6-32969289-T-A, CADD 15.00
- V5V (p.Val5Val), gnomAD 6-32969290-T-C, CADD 13.50
- T6A (p.Thr6Ala), ExAC rs758704519, TOPMed rs758704519, gnomAD rs758704519, REVEL 0.14, CADD 23.40
- T6I (p.Thr6Ile), ExAC rs777834793, TOPMed rs777834793, gnomAD rs777834793, REVEL 0.16, CADD 24.30
- P7L (p.Pro7Leu), cosmic curated COSV10531, 1000Genomes rs142520217, ExAC rs142520217, TOPMed rs142520217, CADD 6.35
- P7S (p.Pro7Ser), rs140566548, ClinGen CA3747951, cosmic curated COSV10469, ClinVar RCV004434290, CADD 2.52, Uncertain significance, not specified
- P7T (p.Pro7Thr), 1000Genomes rs140566548, ESP rs140566548, ExAC rs140566548, TOPMed rs140566548, REVEL 0.11, CADD 24.20, Uncertain significance
- P7R (p.Pro7Arg), gnomAD 6-32969262-C-G, CADD 7.34
- P7H (p.Pro7His), gnomAD 6-32969262-C-A, CADD 7.17
- P7P (p.Pro7Pro), gnomAD 6-32969263-T-A, CADD 7.25
- P7A (p.Pro7Ala), gnomAD 6-32969264-C-G, CADD 2.11
- P7Q (p.Pro7Gln), rs115634162, gnomAD 6-32969271-C-A, CADD 3.79
- H8D (p.His8Asp), rs377684930, NCI-TCGA Cosmic COSV1008, ESP rs377684930, ExAC rs377684930, REVEL 0.20, CADD 20.80, Variant assessed as somatic; moderate impact.
- H8L (p.His8Leu), 1000Genomes rs201319601, ExAC rs201319601, TOPMed rs201319601, gnomAD rs201319601, REVEL 0.20, CADD 21.30
- H8P (p.His8Pro), 1000Genomes rs201319601, ExAC rs201319601, TOPMed rs201319601, gnomAD rs201319601, REVEL 0.16, CADD 22.00
- H8Q (p.His8Gln), 1000Genomes rs554586362, ExAC rs554586362, TOPMed rs554586362, gnomAD rs554586362, REVEL 0.09, CADD 15.80
- H8R (p.His8Arg), 1000Genomes rs201319601, ExAC rs201319601, TOPMed rs201319601, gnomAD rs201319601, REVEL 0.12, CADD 20.20
- H8Y (p.His8Tyr), rs377684930, NCI-TCGA Cosmic COSV1008, cosmic curated COSV10087, ESP rs377684930, REVEL 0.08, CADD 19.30, Variant assessed as somatic; moderate impact.
- N9D (p.Asn9Asp), rs775207207, ClinGen CA3747956, cosmic curated COSV66373, ClinVar RCV004323012, REVEL 0.06, CADD 14.20, Uncertain significance, not specified
- N9K (p.Asn9Lys), 1000Genomes rs748797118, ExAC rs748797118, TOPMed rs748797118, gnomAD rs748797118, REVEL 0.07, CADD 14.90
- K10E (p.Lys10Glu), TOPMed rs1778220122
- K10N (p.Lys10Asn), ExAC rs748209924, TOPMed rs748209924, gnomAD rs748209924, REVEL 0.07, CADD 32.00
- K10T (p.Lys10Thr), cosmic curated COSV66372
- K10K (p.Lys10Lys), gnomAD 6-32969284-A-G, CADD 17.10
- L11F (p.Leu11Phe), TOPMed rs1222181698, REVEL 0.06, CADD 23.70
- L11H (p.Leu11His), gnomAD rs1434620431, REVEL 0.10, CADD 26.70
- L11V (p.Leu11Val), gnomAD 6-32969273-T-G, CADD 8.52
- L11L (p.Leu11Leu), rs1253844213, gnomAD 6-32969273-T-C, CADD 8.80
- P12L (p.Pro12Leu), rs864309591, ClinGen CA248925, ClinVar RCV000202731, TOPMed rs864309591, REVEL 0.14, CADD 20.60, Uncertain significance, not specified
- P12S (p.Pro12Ser), cosmic curated COSV10469, ExAC rs773585882, TOPMed rs773585882, gnomAD rs773585882, REVEL 0.04, CADD 17.40, Uncertain significance, not specified
- G13C (p.Gly13Cys), gnomAD 6-32969279-G-T, CADD 17.20
- G13S (p.Gly13Ser), rs932669747, gnomAD 6-32969279-G-A, CADD 17.50
- G13V (p.Gly13Val), gnomAD 6-32969280-G-T, CADD 17.20
- G13D (p.Gly13Asp), rs1777736408, gnomAD 6-32969280-G-A, CADD 17.50
- G13G (p.Gly13Gly), gnomAD 6-32969281-C-T, CADD 17.60
- G13* (p.Gly13Ter), rs2127495661, gnomAD 6-32969345-G-T, CADD 18.30
- G13A (p.Gly13Ala), gnomAD 6-32969346-G-C, CADD 18.40
- E14A (p.Glu14Ala), rs748849886, ClinGen CA3748026, ClinVar RCV004200365, ExAC rs748849886, CADD 10.30, Uncertain significance, not specified
- E14K (p.Glu14Lys), NCI-TCGA TCGA novel, TOPMed rs1778448470, Variant assessed as somatic; moderate impact.
- E14* (p.Glu14Ter), gnomAD 6-32969276-G-T, CADD 15.20
- E14G (p.Glu14Gly), rs1308294407, gnomAD 6-32969277-A-G, CADD 17.80
- E14E (p.Glu14Glu), gnomAD 6-32969278-G-A, CADD 17.50
- G15R (p.Gly15Arg), TOPMed rs1229532437, gnomAD rs1229532437, REVEL 0.08, CADD 23.40
- N16K (p.Asn16Lys), cosmic curated COSV10087
- N16I (p.Asn16Ile), NCI-TCGA Cosmic COSV6637, cosmic curated COSV66374, Variant assessed as somatic; moderate impact.
- N16Y (p.Asn16Tyr), cosmic curated COSV10469
- A17S (p.Ala17Ser), ExAC rs766690749, TOPMed rs766690749, gnomAD rs766690749, REVEL 0.07, CADD 21.70
- A17V (p.Ala17Val), TOPMed rs927977214, gnomAD rs927977214, REVEL 0.09, CADD 22.60
- A17T (p.Ala17Thr), rs1371221120, gnomAD 6-32969249-G-A, CADD 15.80
- A17D (p.Ala17Asp), gnomAD 6-32969250-C-A, CADD 16.00
- A17G (p.Ala17Gly), gnomAD 6-32969250-C-G, CADD 16.10
- A17A (p.Ala17Ala), rs1406561243, gnomAD 6-32969251-C-T, CADD 15.30
- G18A (p.Gly18Ala), rs776906957, ClinGen CA3748028, ClinVar RCV004129334, ExAC rs776906957, REVEL 0.14, CADD 24.30, Uncertain significance, not specified
- G18E (p.Gly18Glu), rs557774469, gnomAD 6-32969295-G-A, CADD 18.20
- G18V (p.Gly18Val), gnomAD 6-32969295-G-T, CADD 17.90
- G21R (p.Gly21Arg), TOPMed rs913961133, gnomAD rs913961133, REVEL 0.13, CADD 28.50
- G21C (p.Gly21Cys), rs1418439640, gnomAD 6-32969303-G-T, CADD 9.83
- G21D (p.Gly21Asp), gnomAD 6-32969304-G-A, CADD 0.04
- G21V (p.Gly21Val), rs1777739134, gnomAD 6-32969304-G-T, CADD 0.03
- G21G (p.Gly21Gly), gnomAD 6-32969305-C-A, CADD 4.17
- L22V (p.Leu22Val), TOPMed rs1293637803
- G23D (p.Gly23Asp), rs55650502, ClinGen CA3748031, cosmic curated COSV99058, ClinVar RCV000883048, REVEL 0.13, CADD 22.40, Benign, not provided
- G23S (p.Gly23Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P24L (p.Pro24Leu), ESP rs368437378, ExAC rs368437378, TOPMed rs368437378, gnomAD rs368437378, REVEL 0.12, CADD 22.60
- P24S (p.Pro24Ser), TOPMed rs1352133742, REVEL 0.08, CADD 20.70
- P24H (p.Pro24His), rs945327205, gnomAD 6-32969307-C-A, CADD 13.20
- P24P (p.Pro24Pro), rs1170314338, gnomAD 6-32969308-C-T, CADD 15.10
- P24T (p.Pro24Thr), gnomAD 6-32969309-C-A, CADD 14.20
- P24R (p.Pro24Arg), rs1413884027, gnomAD 6-32969310-C-G, CADD 15.70
- E25K (p.Glu25Lys), ESP rs371937442, ExAC rs371937442, TOPMed rs371937442, gnomAD rs371937442, REVEL 0.06, CADD 23.20
- A26V (p.Ala26Val), TOPMed rs1778453265, REVEL 0.06, CADD 22.60
- A28T (p.Ala28Thr), Ensembl rs924069269
- P29A (p.Pro29Ala), gnomAD rs1331082326, REVEL 0.05, CADD 19.30
- G30E (p.Gly30Glu), NCI-TCGA TCGA novel, UniProt VAR 041904, REVEL 0.51, CADD 29.40, Uncertain significance, in a glioblastoma multiforme sample
- G30V (p.Gly30Val), cosmic curated COSV10971
- K31M (p.Lys31Met), cosmic curated COSV10469
- K31R (p.Lys31Arg), gnomAD rs1285702866, REVEL 0.17, CADD 27.20
- R32E (p.Arg32Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R32G (p.Arg32Gly), rs1777737452, gnomAD 6-32969290-TA-T, CADD 12.60
- R16del (p.Arg16del), rs1777737659, gnomAD 6-32969290-TAGG-T, CADD 16.30
- R32A (p.Arg32Ala), rs1260167100, gnomAD 6-32969291-A-AG, CADD 14.10
- R32R (p.Arg32Arg), gnomAD 6-32969291-A-C, CADD 14.30
- R32K (p.Arg32Lys), gnomAD 6-32969292-G-A, CADD 14.30
- R32M (p.Arg32Met), gnomAD 6-32969292-G-T, CADD 13.90
- R32S (p.Arg32Ser), gnomAD 6-32969293-G-T, CADD 16.60
- R32W (p.Arg32Trp), rs573572716, gnomAD 6-32969297-C-T, CADD 12.30
- R32L (p.Arg32Leu), gnomAD 6-32969298-G-T, CADD 13.00
- R32Q (p.Arg32Gln), gnomAD 6-32969298-G-A, CADD 13.40
- R32H (p.Arg32His), gnomAD 6-32969322-G-A, CADD 17.70
- I33F (p.Ile33Phe), gnomAD 6-32969318-A-T, CADD 9.71
- I33T (p.Ile33Thr), gnomAD 6-32969319-T-C, CADD 12.90
- R34G (p.Arg34Gly), gnomAD rs1778456287, REVEL 0.33, CADD 25.30
- R34P (p.Arg34Pro), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10087, Variant assessed as somatic; moderate impact.
- R34Q (p.Arg34Gln), cosmic curated COSV10821, TOPMed rs1417603316, gnomAD rs1417603316, REVEL 0.26, CADD 32.00
- R34S (p.Arg34Ser), gnomAD 6-32971595-A-T, CADD 8.95
- R34I (p.Arg34Ile), gnomAD 6-32971624-G-T, CADD 9.72
- R34C (p.Arg34Cys), rs1490593779, gnomAD 6-32971635-C-T, CADD 7.59
- R34H (p.Arg34His), gnomAD 6-32971636-G-A, CADD 7.86
- R34L (p.Arg34Leu), gnomAD 6-32971636-G-T, CADD 7.39
- P36A (p.Pro36Ala), gnomAD rs1225975115, REVEL 0.17, CADD 22.80
- P36L (p.Pro36Leu), ExAC rs779883033, TOPMed rs779883033, gnomAD rs779883033, REVEL 0.25, CADD 22.80
- P36R (p.Pro36Arg), ExAC rs779883033, TOPMed rs779883033, gnomAD rs779883033, REVEL 0.23, CADD 23.80
- P36S (p.Pro36Ser), gnomAD rs1225975115, REVEL 0.22, CADD 23.50
- S37F (p.Ser37Phe), TOPMed rs902105343, REVEL 0.19, CADD 26.60
- S37Y (p.Ser37Tyr), cosmic curated COSV66374
- S37A (p.Ser37Ala), gnomAD 6-32969249-GC-G, CADD 15.60
- S37R (p.Ser37Arg), gnomAD 6-32969252-A-C, CADD 11.40
- S37G (p.Ser37Gly), rs2127495495, gnomAD 6-32969252-A-G, CADD 11.80
- S37N (p.Ser37Asn), gnomAD 6-32969253-G-A, CADD 10.50
- S37I (p.Ser37Ile), gnomAD 6-32969253-G-T, CADD 9.97
- S37S (p.Ser37Ser), rs115460679, gnomAD 6-32969254-C-T, CADD 11.60
- L38I (p.Leu38Ile), NCI-TCGA TCGA novel, TOPMed rs1778458771, Variant assessed as somatic; moderate impact.
- L38R (p.Leu38Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L39F (p.Leu39Phe), gnomAD rs1287500847, REVEL 0.19, CADD 24.30
- L39S (p.Leu39Ser), ESP rs376209743, gnomAD rs376209743
- L39W (p.Leu39Trp), ESP rs376209743, gnomAD rs376209743
- L39Y (p.Leu39Tyr), gnomAD 6-32971613-CT-C, CADD 1.01
- L39L (p.Leu39Leu), rs923359562, gnomAD 6-32971614-T-C, CADD 3.64
- Y40C (p.Tyr40Cys), 1000Genomes rs200307380, ExAC rs200307380, TOPMed rs200307380, gnomAD rs200307380, REVEL 0.18, CADD 25.60
- Y40H (p.Tyr40His), rs1358584753, gnomAD 6-32969267-T-C, CADD 12.70
- Y40Y (p.Tyr40Tyr), gnomAD 6-32969269-C-T, CADD 8.59
- Y40* (p.Tyr40Ter), rs1212819054, gnomAD 6-32969269-C-A, CADD 8.04
- Y40L (p.Tyr40Leu), rs771357755, gnomAD 6-32969304-G-GC, CADD 4.19
- Y40I (p.Tyr40Ile), rs771357755, gnomAD 6-32969304-GC-G, CADD 3.52
- E41D (p.Glu41Asp), TOPMed rs879045467, gnomAD rs879045467
- E41K (p.Glu41Lys), ExAC rs778053233, TOPMed rs778053233, gnomAD rs778053233, REVEL 0.39, CADD 32.00
- G42R (p.Gly42Arg), gnomAD 6-32971650-G-C, CADD 9.21
- G42S (p.Gly42Ser), rs1777992734, gnomAD 6-32971650-G-A, CADD 9.57
- G42C (p.Gly42Cys), gnomAD 6-32971650-G-T, CADD 9.09
- G42V (p.Gly42Val), gnomAD 6-32971651-G-T, CADD 10.40
- F43L (p.Phe43Leu), gnomAD 6-32971595-A-AT, CADD 10.70
- F43V (p.Phe43Val), gnomAD 6-32971596-T-G, CADD 13.20
- F43C (p.Phe43Cys), rs1392838016, gnomAD 6-32971597-T-G, CADD 13.00
- F43F (p.Phe43Phe), rs757068397, gnomAD 6-32971598-C-T, CADD 13.10
- F43S (p.Phe43Ser), rs1777984770, gnomAD 6-32971600-T-C, CADD 10.50
- E44K (p.Glu44Lys), cosmic curated COSV66374
- S45R (p.Ser45Arg), ExAC rs747061505, TOPMed rs747061505, gnomAD rs747061505, REVEL 0.12, CADD 24.20
- P46L (p.Pro46Leu), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10087, Variant assessed as somatic; moderate impact.
- P46T (p.Pro46Thr), rs1235563749, gnomAD 6-32971615-T-TA, CADD 6.93
- P46S (p.Pro46Ser), rs1172889106, gnomAD 6-32971617-C-T, CADD 8.09
- P46Q (p.Pro46Gln), gnomAD 6-32971618-C-A, CADD 0.09
- P46P (p.Pro46Pro), rs199600996, gnomAD 6-32971619-G-A, CADD 8.97
- P46R (p.Pro46Arg), rs201226550, gnomAD 6-32971621-C-G, CADD 3.09
- T47T (p.Thr47Thr), rs1057171544, gnomAD 6-32971628-C-T, CADD 0.48
- p.Thr48 Thr49insAla, gnomAD 6-32971629-A-ACAG, CADD 5.93
- T47P (p.Thr47Pro), gnomAD 6-32971629-AC-A, CADD 5.30
- T47A (p.Thr47Ala), gnomAD 6-32971629-A-G, CADD 8.22
- T47N (p.Thr47Asn), gnomAD 6-32971630-C-A, CADD 6.33
- T47I (p.Thr47Ile), rs1777990098, gnomAD 6-32971630-C-T, CADD 6.95
- M48T (p.Met48Thr), rs1161629101, ClinGen CA363600343, ClinVar RCV004434288, gnomAD rs1161629101, REVEL 0.15, CADD 23.80, Uncertain significance, not specified
- M48V (p.Met48Val), cosmic curated COSV10087, ESP rs369193752, gnomAD rs369193752, REVEL 0.11, CADD 23.30, Uncertain significance, not specified
- A49V (p.Ala49Val), cosmic curated COSV66374, TOPMed rs1778461857, CADD 7.81
- A49E (p.Ala49Glu), cosmic curated COSV10469
- A49G (p.Ala49Gly), rs3918144, cosmic curated COSV66374, UniProt VAR 041905, 1000Genomes rs3918144, REVEL 0.13, CADD 23.00
- A49S (p.Ala49Ser), rs55669504, cosmic curated COSV66374, UniProt VAR 041906, 1000Genomes rs55669504, REVEL 0.10, CADD 19.10
- p.Ala42dup, rs756580191, gnomAD 6-32971601-C-CGCT, CADD 10.00
Public BRD2 analysis runs
- BRD2 analysis run — BRD2 (1,692 variants) — completed 2026-08-20